Version 1
: Received: 24 July 2024 / Approved: 25 July 2024 / Online: 25 July 2024 (07:19:49 CEST)
How to cite:
Jones, O. Y. Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints2024, 2024072016. https://doi.org/10.20944/preprints202407.2016.v1
Jones, O. Y. Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints 2024, 2024072016. https://doi.org/10.20944/preprints202407.2016.v1
Jones, O. Y. Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints2024, 2024072016. https://doi.org/10.20944/preprints202407.2016.v1
APA Style
Jones, O. Y. (2024). Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review. Preprints. https://doi.org/10.20944/preprints202407.2016.v1
Chicago/Turabian Style
Jones, O. Y. 2024 "Single Center Based Real-World Experience on ANTI-IL 1 Biological Response Modifiers: A Case Series and Literature Review" Preprints. https://doi.org/10.20944/preprints202407.2016.v1
Abstract
This communication is to summarize our single center experience on applications of anti-IL-1 biologic response modifiers on autoimmune and autoinflammatory conditions in children. We present our rationale for off-label utilization of Anakinra and discuss evolving treatment paradigms that warrants further research and validation. Based on our observations and successful treatment outcomes, we advocate future multilateral efforts to liberate access to anti-IL-1 medications to control inordinate and detrimental inflammation in children.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.